X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1235) 1235
female (839) 839
male (838) 838
middle aged (756) 756
aged (694) 694
uracil - administration & dosage (544) 544
adult (529) 529
oncology (525) 525
uracil - analogs & derivatives (488) 488
antineoplastic combined chemotherapy protocols - therapeutic use (470) 470
tegafur - administration & dosage (422) 422
uracil - adverse effects (406) 406
antineoplastic combined chemotherapy protocols - adverse effects (359) 359
chemotherapy (347) 347
uracil - therapeutic use (319) 319
treatment outcome (307) 307
cancer (276) 276
uracil (238) 238
administration, oral (236) 236
5-fluorouracil (231) 231
tegafur - adverse effects (230) 230
drug combinations (223) 223
fluorouracil (213) 213
pharmacology & pharmacy (213) 213
aged, 80 and over (210) 210
animals (208) 208
fluorouracil - administration & dosage (204) 204
leucovorin - administration & dosage (195) 195
drug administration schedule (190) 190
antineoplastic combined chemotherapy protocols - administration & dosage (180) 180
toxicity (172) 172
uft (171) 171
colorectal neoplasms - drug therapy (170) 170
care and treatment (164) 164
patients (158) 158
drug therapy, combination (156) 156
colorectal cancer (150) 150
fluorouracil - adverse effects (141) 141
leucovorin (135) 135
therapy (134) 134
carcinoma (124) 124
neoplasm staging (123) 123
radiotherapy (123) 123
research (123) 123
survival rate (123) 123
medicine & public health (119) 119
surgery (119) 119
tegafur - therapeutic use (119) 119
trial (119) 119
analysis (117) 117
chemotherapy, adjuvant (117) 117
disease-free survival (115) 115
hematology, oncology and palliative medicine (114) 114
adenocarcinoma - drug therapy (110) 110
capecitabine (106) 106
diabetes mellitus, type 2 - drug therapy (106) 106
cisplatin - administration & dosage (105) 105
uracils (103) 103
radiology, nuclear medicine & medical imaging (101) 101
antimetabolites, antineoplastic - adverse effects (100) 100
dose-response relationship, drug (100) 100
tegafur (100) 100
clinical trials (98) 98
colorectal neoplasms - pathology (98) 98
radiology and nuclear medicine (98) 98
prospective studies (96) 96
uracil - pharmacology (96) 96
drug therapy (94) 94
antimetabolites, antineoplastic - administration & dosage (93) 93
retrospective studies (93) 93
combined modality therapy (92) 92
radiology (88) 88
pyrimidines (86) 86
cisplatin (85) 85
piperidines - therapeutic use (85) 85
medicine (84) 84
metastasis (82) 82
pharmacokinetics (80) 80
survival (80) 80
uracil - pharmacokinetics (79) 79
deoxycytidine - analogs & derivatives (78) 78
time factors (78) 78
genotype (77) 77
health aspects (76) 76
hepatitis c, chronic - drug therapy (76) 76
efficacy (75) 75
fluorouracil - therapeutic use (74) 74
mice (74) 74
survival analysis (74) 74
antimetabolites, antineoplastic - therapeutic use (73) 73
leucovorin - adverse effects (73) 73
pharmacology/toxicology (73) 73
risk factors (73) 73
stomach neoplasms - drug therapy (73) 73
piperidines - adverse effects (72) 72
toxicology (72) 72
follow-up studies (71) 71
randomized-trial (71) 71
adjuvant chemotherapy (70) 70
antineoplastic agents - adverse effects (70) 70
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1351) 1351
Japanese (144) 144
Russian (27) 27
French (10) 10
German (8) 8
Chinese (3) 3
Italian (3) 3
Spanish (3) 3
Hungarian (2) 2
Polish (2) 2
Czech (1) 1
Dutch (1) 1
Portuguese (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European journal of gastroenterology & hepatology, ISSN 0954-691X, 10/2018, Volume 30, Issue 10, pp. 1177 - 1186
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 17, pp. 1594 - 1603
.... Serious adverse events and treatment discontinuation were infrequent. Approximately 184 million people worldwide have chronic hepatitis C virus (HCV... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Expert Review of Anti-infective Therapy, ISSN 1478-7210, 07/2014, Volume 12, Issue 7, pp. 763 - 773
About 2% of the world's population is estimated to be chronically infected with hepatitis C virus (HCV). These chronic carriers are at risk of developing liver... 
interferon-free | ledipasvir | sofosbuvir | MK-8742 | ombitasvir | MK-5172 | ABT-450 | asunaprevir | dasabuvir | daclatasvir | Daclatasvir | Ombitasvir | Interferon-free | Ledipasvir | Asunaprevir | Sofosbuvir | Dasabuvir | CONTROLLED-TRIAL | PLUS RIBAVIRIN | LIVER-TRANSPLANTATION | HCV INFECTION | SUSTAINED VIROLOGICAL RESPONSE | PROTEASE INHIBITOR | TREATMENT OPTIONS | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | CHRONIC VIRAL-HEPATITIS | DISEASE PROGRESSION | Uridine Monophosphate - administration & dosage | Quinoxalines - adverse effects | Anilides - therapeutic use | Isoquinolines - adverse effects | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Imidazoles - administration & dosage | Benzofurans - administration & dosage | Carbamates - administration & dosage | Uracil - administration & dosage | Ribavirin - administration & dosage | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Hepatitis C - prevention & control | Quinoxalines - therapeutic use | Uridine Monophosphate - therapeutic use | Disease Eradication | Benzofurans - therapeutic use | Quinoxalines - administration & dosage | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Macrocyclic Compounds - adverse effects | Antiviral Agents - administration & dosage | Benzofurans - adverse effects | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Anilides - administration & dosage | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Carbamates - adverse effects | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Hepacivirus | Isoquinolines - administration & dosage | Drug Combinations | Sulfonamides - administration & dosage | Uracil - analogs & derivatives
Journal Article
Contemporary Clinical Trials, ISSN 1551-7144, 2017, Volume 57, pp. 58 - 68
... (T4), 12 months post-treatment (T5). Outcomes (1) Changes in side effects, functioning, pre-existing conditions, and out-of-pocket costs during therapy (T1 vs T2/T3); (2... 
Hematology, Oncology and Palliative Medicine | Cardiovascular | Hepatitis | Direct acting antiviral (DAA) | Patient-reported outcomes | Patient-centered outcomes research (PCOR) | Liver | UNITED-STATES | MEDICINE, RESEARCH & EXPERIMENTAL | REPORTED OUTCOMES | VIRUS-INFECTION | HCV GENOTYPE 1 | SYMPTOM PREVALENCE | NATIONAL-HEALTH | INFORMATION-SYSTEM PROMIS | PSYCHOMETRIC EVALUATION | ROBUST ESTIMATION | PHARMACOLOGY & PHARMACY | QUALITY-OF-LIFE | Quinoxalines - adverse effects | Prospective Studies | Humans | Patient Participation | Fluorenes - therapeutic use | Male | Ritonavir - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Patient-Centered Care - methods | Ritonavir - therapeutic use | Adult | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Uridine Monophosphate - therapeutic use | Sofosbuvir - therapeutic use | Benzofurans - therapeutic use | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Uracil - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Benzofurans - adverse effects | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Sulfonamides - adverse effects | Carbamates - adverse effects | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Medicine, Experimental | Medical research | Antiviral agents | Hepatitis C | Drug therapy | Hepatitis C virus | Analysis | patient-reported outcomes | patient-centered outcomes research (PCOR) | hepatitis | direct acting antiviral (DAA)
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 67, Issue 4, pp. 700 - 707
Journal Article
Contemporary Clinical Trials, ISSN 1551-7144, 2011, Volume 32, Issue 3, pp. 324 - 332
... diabetes drugs [2] and more recently to recommend a risk assessment and mitigation strategy for rosiglitazone [3] . An immediate effect of the guidelines was a pathway... 
Hematology, Oncology and Palliative Medicine | Cardiovascular | Saxagliptin and liraglutide | Sitagliptin | Alogliptin | Vildagliptin | Insulin inhalation powder | Exenatide | MEDICINE, RESEARCH & EXPERIMENTAL | PHARMACOLOGY & PHARMACY | Triazoles - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | United States | Humans | Pyrrolidines - adverse effects | Allylamine - adverse effects | Randomized Controlled Trials as Topic - standards | Time Factors | Investigational New Drug Application - legislation & jurisprudence | Sitagliptin Phosphate | Incretins - chemistry | Colesevelam Hydrochloride | Incretins - physiology | United States Food and Drug Administration | Adamantane - adverse effects | Adamantane - analogs & derivatives | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Dipeptides - adverse effects | Allylamine - analogs & derivatives | Uracil - adverse effects | Piperidines - adverse effects | Pyrazines - adverse effects | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Liraglutide | Peptides - adverse effects | Practice Guidelines as Topic | Uracil - analogs & derivatives | Type 2 diabetes | Hypoglycemic agents | Drug therapy | Cardiovascular diseases | Drug approval | Risk factors | Diabetes therapy
Journal Article
International journal of radiation oncology, biology, physics, ISSN 0360-3016, 2013, Volume 86, Issue 1, pp. 27 - 33
...) in reducing grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15... 
Radiology | Hematology, Oncology and Palliative Medicine | CANCER-PATIENTS | ONCOLOGY | CONCURRENT CHEMOTHERAPY | RANDOMIZED-TRIAL | TOXICITY | RADIOTHERAPY | FLUOROURACIL | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Chemoradiotherapy - adverse effects | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Urogenital System - radiation effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Gastrointestinal Tract - radiation effects | Male | Anal Canal | Carcinoma, Squamous Cell - diagnostic imaging | Carcinoma, Transitional Cell - therapy | Radiotherapy, Intensity-Modulated - adverse effects | Radiotherapy Planning, Computer-Assisted - standards | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Aged, 80 and over | Anus Neoplasms - therapy | Adult | Dose Fractionation | Female | Mitomycin - adverse effects | Chemoradiotherapy - methods | Anus Neoplasms - diagnostic imaging | Drug Administration Schedule | Radiotherapy, Intensity-Modulated - methods | Carcinoma, Squamous Cell - therapy | Anus Neoplasms - pathology | Radiography | Analysis of Variance | Carcinoma, Transitional Cell - pathology | Radiation Injuries - prevention & control | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasm Staging | Mitomycin - administration & dosage | Sects | Mitomycin | Nuclear radiation | Analysis | Clinical trials | Radiotherapy | Cancer | Fluorouracil | Index Medicus | AUGER ELECTRON SPECTROSCOPY | REVIEWS | PATIENTS | DISEASE INCIDENCE | URACILS | RADIATION QUALITY | METASTASES | MITOMYCIN | RADIATION DOSES | PLANNING | CARCINOMAS | RADIOLOGY AND NUCLEAR MEDICINE
Journal Article
BMC infectious diseases, ISSN 1471-2334, 2018, Volume 18, Issue 1, pp. 580 - 9
According to the EASL and AASLD guidelines, the recommended treatment for patients who failed to achieve a sustained virologic response (SVR) on prior... 
Retreatment | Chronic hepatitis C | Protease inhibitors | Liver cirrhosis | Sustained virologic response | Anilides - adverse effects | Humans | Middle Aged | Fluorenes - therapeutic use | Interferons - adverse effects | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Poland - epidemiology | Young Adult | Ritonavir - adverse effects | Uracil - administration & dosage | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Drug Resistance, Multiple, Viral - drug effects | Hepacivirus - drug effects | Ritonavir - administration & dosage | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Uracil - adverse effects | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Treatment outcome | Hepatitis C | Drug therapy | Analysis | Effectiveness | Ritonavir | Liver | Infections | Proteinase inhibitors | Drug resistance | Patients | Ribavirin | Genotype & phenotype | Hepatitis | Protease | Gastroenterology | Fibrosis | Interferon | Safety | Genotypes
Journal Article
Clinical therapeutics, ISSN 0149-2918, 2014, Volume 36, Issue 12, pp. 2072 - 2079
...Introduction Before the controversy over the cardiovascular effects of the thiazolidinezones, government regulatory agencies did not require hypoglycemic drugs... 
Internal Medicine | Medical Education | DPP-IV inhibition | cardiovascular disease | heart failure | type 2 diabetes | Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) | Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD) | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | MYOCARDIAL-INFARCTION | SAXAGLIPTIN | HUMANS | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | IMPACT | CLINICAL-TRIALS | IMPROVES | PHARMACOLOGY & PHARMACY | TYPE-2 DIABETES-MELLITUS | CARDIOVASCULAR RISK | Dipeptides - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrrolidines - adverse effects | Uracil - therapeutic use | Hospitalization | Pyrrolidines - therapeutic use | Uracil - adverse effects | Piperidines - therapeutic use | Piperidines - adverse effects | Adamantane - therapeutic use | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Heart Failure - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Nitriles - therapeutic use | Sitagliptin Phosphate - adverse effects | Uracil - analogs & derivatives | Heart failure | Regulatory agencies | Heart attacks | Peptides | Mortality | Cardiovascular disease | FDA approval | Patients | Studies | Databases | Diabetes | Drug therapy | Acute coronary syndromes
Journal Article
Journal of the American Pharmacists Association, ISSN 1544-3191, 2015, Volume 55, Issue 2, pp. 216 - 223
Journal Article
13.